Levamisole effects on major histocompatibility complex and adhesion molecule expression and on myeloid cell adhesion to human colon tumor cell lines

Journal of the National Cancer Institute

Volumn 88, Issue 2, 1996, Pages 109-116

  Kimball, Edward S ^a   Fisher, M Carolyn ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LEVAMISOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CELL INTERACTION; COLON CANCER; DRUG EFFECT; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKOCYTE ADHERENCE; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; CELL ADHESION; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; LEVAMISOLE; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MELANOMA; RECEPTORS, LYMPHOCYTE HOMING; TUMOR CELLS, CULTURED; UMBILICAL VEINS; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0030048770     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.2.109     Document Type: Article

References (31)

1. Vanky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 1990;31:19-27.
2. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:425-34.
3. Staunton DE, Martin SD, Stratowa C. Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 1988;52:925-33.
4. Buckle AM, Hogg N. Human memory T cells express intercellular adhesion molecule-1 which can be increased by interleukin 2 and interferongamma. Eur J Immunol 1990;20:337-41.
5. Möst J, Schwaeble W, Drach J. Sommerauer A, Dierich MP. Regulation of the expression of ICAM-1 on human monocytes and monocytic tumor cell lines. J Immunol 1992;148:1635-42.
6. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1. and tumor necrosis factor-α increases neutrophil adherence by a CDw18-dependem mechanism. J Immunol 1986;136:4548-53.
7. Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 1987;5:223-52.
8. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-I. Nature 1989;341:619-24.
9. Kuhlman P, Moy VT. Lollo BA, Brian AA. The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation. J Immunol 1991;146:1773.
10. Stacker SA, Springer TA. Leukocyte integrin p150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endolhelium. J Immunol 1991;146:648-55.
11. Vennegoor CJ, Van de Wiel-van Kemenade E, Huijbens RJ, Sanchez-Madrid F, Melief CJ, Figdor CG. Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. J Immunol 1992;148:1093-101.
12. Sanchez-Madrid F, Nagy J, Robbins E, Simon P, Springer TA. A human leukocyte differentiation antigen family with distinct alpha subunits and a common beta subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKMI/MAC-1), and the p 150,95 molecule. J Exp Med 1983;158:1785-803.
13. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p 150,95 glycoproteins. Annu Rev Med 1987;38:175-94.
14. Webb DS, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of [CAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991;146:3682-6.
15. Bouillon M, Tessier P, Boulianne R, Destrempe R, Audetle M. Regulation by retinoic acid of ICAM-1 expression on human tumor cell lines. Biochim Biophys Acta 1991;1097:95-102.
16. Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meassa R, Canevari S, et al. The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int J Cancer 1994;56:846-52.
17. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60:577-84.
18. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. α4/β1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol 1992;149:1424-31.
19. Amery WK, Horig C, Levamisole. In: Fenichel RL, Chirigos MA, editors. Immune modulating agents and their mechanisms. New York: Marcel Dekker, 1984:383.
20. Goodrich KH, Alvarez X, Holcombe RF. Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. Cancer 1993;72:225.
21. Schiller JH, Lindstrom M, Witt PL, Hank JA, Mahvi D, Wagner RJ, et al. Immunological effects of levamisole in vitro. J Immunother 1991;10:297-306.
22. Abdalla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line [see comment citation in Medline] [published erratum appears in J Natl Cancer Inst 1995;87:848]. J Natl Cancer Inst 1995;87:489-96.
23. Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A. B antigens in vascular endothelial cells and dermal fihroblasts in vitro. Proc Natl Acad Sci U S A 1986;83:446-50.
24. Luyckx M, Rousseaux F, Cazin M, Brunei C, Cazin JC. Haguenoer JM. et al. Pharmaeokinetics of levamisole in healthy subjects and cancer patients. EurJ Drug Metab Pharrnacokinet 1982;7:247-54.
25. Renoux G, Renoux M. Modulation of immune reactivity by phenyl-imidothiazole salts in mice immunized by sheep red blood cells. J Immunol 1974;113:779-90.
26. Janik J, Kopp WC, Smith JW 2d, Longo DL, Alvord WG, Sharfmen WH, et al. Dose-related immunologic effects of levumisole in patients with cancer. J Clin Oncol 1993;11:125-35.
27. Hawkyard SJ, James KS, Prescott S, Jackson AM, Smyth JF. Chisolm GD. The effects of recombinant human interferon-gamma on the growth of a panel of human bladder cancer cell lines. J Urol 1991;145:1078-81.
28. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA. Goodman PJ, et al. Levamisole and fluurouracil for adjuvant therapy of resected colon carcinoma [see comment citations in Medline], N Engl J Med 1990;322:352-8.
29. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and te combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic [see comment citation in Medline]. J Clin Oncol 1989;:1447-56.
30. Holcombe RF, Stewart RM, Betzng KW, Kannan K. Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother 1994;8:394-8.
31. Chong AS. Boussy IA, Jiang XL, Lamas M, Graf LH. CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxocily. Cell Immunol 1994; 157:92-105.